Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOFOL vs DESFLURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in the ICU,Procedural sedation (e.g., during diagnostic or therapeutic procedures),Treatment of refractory status epilepticus (off-label),Management of severe agitation or delirium (off-label)
Maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Induction of anesthesia in adults and pediatric patients
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Primarily hepatic via conjugation to glucuronide and sulfate; also metabolized by CYP2B6 and CYP2C9. Metabolites are renally excreted.
Minimal hepatic metabolism (<0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
95-99% bound primarily to albumin (≈48%) and alpha-1-acid glycoprotein (≈50%), with minor binding to lipoproteins.
Approximately 5–10% bound to plasma proteins (primarily albumin).
Initial Vd: 0.2-0.4 L/kg (central compartment); steady-state Vd: 2-10 L/kg (extensive tissue distribution).
Vd approximately 0.2–0.5 L/kg (small, reflecting limited tissue distribution; consistent with lipophilic but rapidly equilibrating profile).
IV: 100%; enteral: negligible due to first-pass metabolism; oral bioavailability <1%.
Inhalation: ~100% bioavailable into systemic circulation via lungs.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, use with caution due to propylene glycol accumulation, monitor for metabolic acidosis.
No dosage adjustment required for renal impairment; desflurane is minimally metabolized and not dependent on renal excretion.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce by 75% due to prolonged clearance and risk of hypotension.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased hepatotoxicity, but no dose modification guidelines exist.
Induction: 2.5-3.5 mg/kg IV over 30 sec. Maintenance: 125-300 mcg/kg/min for age <3 years; 100-200 mcg/kg/min for age 3-12 years. For sedation: 25-100 mcg/kg/min.
Induction: 3-12% inhaled (up to 18% for mask induction); maintenance: 3-6% inhaled; adjust based on age and response; higher MAC requirements in infants.
Reduce induction dose to 1-1.5 mg/kg IV; decrease infusion rate by 20-50% due to reduced clearance and increased sensitivity.
Reduce dose by 20-30% compared to younger adults; typical maintenance 2-5% inhaled; lower MAC (approx 4.5% at 65 years); monitor for hypotension and bradycardia.
No FDA black box warnings.
Desflurane is not indicated for induction of general anesthesia in pediatric patients due to a high incidence of laryngospasm and upper airway adverse events.
Hypotension and bradycardia: may require fluid resuscitation or vasopressors,Respiratory depression and apnea: must have airway management equipment available,Propofol infusion syndrome (PRIS): rare but fatal with high doses >4 mg/kg/hr for >48 hours; characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure,Risk of pancreatitis: monitor lipase if symptoms develop,Abrupt discontinuation may cause withdrawal symptoms after prolonged use,Not recommended for use in patients with propofol allergy or egg/soybean oil hypersensitivity (formulation contains egg lecithin and soybean oil)
Malignant hyperthermia,Respiratory depression and airway complications,Cardiovascular depression (hypotension, bradycardia),QT prolongation,Hepatotoxicity (rare),Rising carbon monoxide levels with dry absorbents,Neurotoxicity in pediatric patients,Renal toxicity (rare)
Hypersensitivity to propofol or any component of the formulation (including egg lecithin, soybean oil, or disodium edetate),Patients with severe lipid metabolism disorders (e.g., pancreatitis with hypertriglyceridemia),Not for use in general anesthesia in obstetrics (crosses placenta; may cause neonatal depression),Relative: hypovolemia, hemodynamic instability, increased intracranial pressure (use with caution)
Known sensitivity to desflurane or other halogenated anesthetics,History of malignant hyperthermia,Refractory hypovolemia,Increased intracranial pressure (relative),Concomitant use with adrenergic agents (risk of arrhythmias)
No specific food restrictions. However, propofol is formulated in a lipid emulsion containing soybean oil and egg lecithin, which may interact with high-fat meals theoretically but not clinically significant. Avoid alcohol for 24 hours post-procedure due to additive sedative effects.
No known food interactions. However, patients should follow preoperative fasting guidelines (nil per os for at least 2 hours for clear liquids and 6-8 hours for solid foods) to reduce the risk of pulmonary aspiration during anesthesia.
First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second trimester: No clear evidence of fetal harm. Third trimester: Use may cause neonatal respiratory depression, hypotonia, and neurobehavioral effects; risk of fetal bradycardia and hypoxia. Propofol crosses the placenta rapidly.
Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal heart rate variability, and neonatal respiratory depression. It is pregnancy category B, but caution is advised.
Propofol is excreted into breast milk in very low concentrations, with an estimated M/P ratio of 1.2-1.5. The relative infant dose is <0.1% of weight-adjusted maternal dose. Consider discarding milk for 24 hours after administration due to potential sedative effects on the infant.
Desflurane is minimally excreted into breast milk; M/P ratio is unknown. It is considered compatible with breastfeeding due to rapid elimination from the mother and low oral bioavailability in the infant. However, monitor for neonatal sedation.
Pregnancy increases volume of distribution and clearance of propofol by 20-50%, primarily due to increased cardiac output and hepatic blood flow. Induction doses may need to be increased by 15-30% to achieve desired effect. Maintenance infusion rates may also require upward titration.
No specific dose adjustment for desflurane in pregnancy, but the minimum alveolar concentration (MAC) is reduced by approximately 25-40% due to increased progesterone and other factors. Lower doses may be required to achieve desired anesthetic depth.
Propofol causes dose-dependent respiratory depression and apnea; always have airway equipment ready. It reduces cerebral metabolic rate and intracranial pressure, making it useful for neuroanesthesia. Pain on injection is common, particularly in small veins; consider lidocaine pretreatment. Propofol infusion syndrome (PRIS) is a rare but fatal complication with prolonged high-dose infusions (>48h, >4 mg/kg/h), characterized by lactic acidosis, rhabdomyolysis, and cardiac failure. Avoid in patients with egg or soy allergy due to lipid emulsion. Use the lower dose for elderly or hemodynamically unstable patients. Monitor triglyceride levels with prolonged use.
Desflurane has the lowest blood-gas partition coefficient among volatile anesthetics, resulting in the fastest onset and emergence. Its pungent odor limits use for inhalation induction, especially in children. Due to its high vapor pressure, a specialized heated vaporizer is required. Desflurane can cause sympathetic nervous system activation at high concentrations, leading to tachycardia and hypertension. It is metabolized minimally (0.02%), but can produce carbon monoxide when exposed to dried CO2 absorbents; desiccated absorbents should be avoided. Malignant hyperthermia risk is present, so dantrolene should be available.
This medication will cause you to feel very sleepy and lose consciousness quickly.,You may experience a burning or stinging sensation at the injection site; this is common.,Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,You might feel groggy, dizzy, or have a headache after waking up.,Inform your doctor if you have any allergies, especially to eggs, soy, or peanuts.,If you will be receiving this medication for a prolonged period, your doctor will monitor your heart, kidneys, and blood tests.
You will receive desflurane gas through a mask or breathing tube to keep you asleep during surgery.,Desflurane has a strong smell; you may notice an odor as you fall asleep.,You will wake up quickly after the anesthetic is stopped, but you may feel drowsy or confused initially.,Potential side effects include nausea, vomiting, shivering, and a temporary increase in heart rate or blood pressure.,Inform your doctor if you have a personal or family history of malignant hyperthermia (a severe reaction to anesthesia).,Do not eat or drink before surgery as instructed to prevent aspiration.
"Propofol, a general anesthetic, may inhibit CYP2C8, the primary enzyme responsible for rosiglitazone metabolism, leading to decreased clearance and elevated plasma concentrations of rosiglitazone. This interaction can potentiate the hypoglycemic effects of rosiglitazone, increasing the risk of hypoglycemia. Clinical vigilance is warranted when these agents are coadministered, especially in patients with diabetes."
"The combination of propofol and methyldopa can lead to an increased risk of severe hypotension and bradycardia due to additive cardiovascular depressant effects. Propofol causes peripheral vasodilation and direct myocardial depression, while methyldopa reduces sympathetic outflow and depletes catecholamines, enhancing propofol's hemodynamic effects. This interaction may result in profound hypotension, reduced cardiac output, and risk of organ hypoperfusion during anesthesia induction and maintenance."
"Propofol, a GABA-A receptor agonist and general anesthetic, depresses myocardial contractility and reduces systemic vascular resistance, leading to hypotension and bradycardia. Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, can blunt the compensatory tachycardia in response to propofol-induced vasodilation and myocardial depression. Concurrent use may result in additive negative chronotropic and inotropic effects, potentially causing severe bradycardia, hypotension, or reduced cardiac output, especially in patients with compromised cardiac function or hypovolemia."
"Concurrent use of buspirone and desflurane may potentiate the hypotensive and bradycardic effects of desflurane, increasing the risk of hemodynamic instability during anesthesia induction or maintenance. Buspirone's serotonergic activity can also lower seizure threshold, potentially interacting with the anesthetic properties of desflurane to cause perioperative seizures or arrhythmias. Clinically, this combination requires careful cardiovascular monitoring and dose adjustment of desflurane to avoid excessive hypotension, bradycardia, or delayed emergence."
"Concomitant use of Desflurane and Triprolidine may lead to enhanced central nervous system (CNS) depression and potential respiratory compromise. Desflurane, a volatile anesthetic, depresses the CNS and respiratory drive, while Triprolidine, a first-generation antihistamine, adds sedative and anticholinergic effects. This synergistic interaction increases the risk of excessive sedation, hypotension, and respiratory depression, particularly during induction or recovery from anesthesia. Clinically, patients may experience prolonged emergence, worsened cognitive function, and increased need for ventilatory support."
"Concomitant administration of desflurane, a volatile halogenated anesthetic, with oxprenolol, a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity, can lead to additive negative inotropic and chronotropic effects on the myocardium, resulting in significant hypotension and bradycardia. This interaction occurs because desflurane depresses myocardial contractility and heart rate directly, while oxprenolol blocks compensatory sympathetic responses, potentially compromising cardiac output and tissue perfusion. Clinicians should be vigilant for exaggerated cardiovascular depression, especially during induction or changes in anesthetic depth."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPOFOL vs DESFLURANE, answered by our medical review team.
PROPOFOL is a General Anesthetic that works by Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.. DESFLURANE is a General Anesthetic that works by Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPOFOL and DESFLURANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPOFOL is: Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.. The standard adult dose of DESFLURANE is: Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PROPOFOL and DESFLURANE. The risk or severity of adverse effects can be increased when Propofol is combined with Desflurane. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PROPOFOL is classified as Category A/B. First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second tr. DESFLURANE is classified as Category C. Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal hear. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.